Skip to main content
Saranya Chumsri, MD, Oncology, Jacksonville, FL, Mayo Clinic Hospital in Florida

SaranyaChumsriMD

Oncology • Jacksonville, FL

Breast Cancer, Hematologic Oncology

Associate Professor, Mayo Clinic

Join to view full profile

Dr. Chumsri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Chumsri's full profile

Already have an account?

Summary

  • Saranya Chumsri, M.D. is an expert in breast cancer research. Her research is focusing on several aspects of breast cancer, including genomics, immunologic, epigenetics, breast cancer stem cells, endocrine resistance, as well as an aggressive form of breast cancer lacking estrogen receptor, progesterone receptor, and HER2, termed triple-negative breast cancer (TNBC). Dr. Chumsri also is an expert in developing genomic biomarkers, using RNA-seq and NanoString technologies, to predict response to targeted therapy in breast cancer, particularly immune-related biomarkers, as well as to identify mechanisms of resistance to targeted therapy. Furthermore, she also developed multiple novel experimental therapeutics in breast cancer through phase I and II clinical trials with a specific focus on immunotherapy, cancer vaccines, TNBC, and endocrine-resistant breast cancer. Combinatorial studies to evaluate the benefit of combining novel therapies in both preclinical and clinical trials.
    As a part of her focus on breast cancer research, Dr. Chumsri is a clinician scientist reviewer for the Breast Cancer Research Program (BCRP) for the Department of Defense Congressionally Directed Medical Research Programs (CDMRP). She was also the Co-leader disease-oriented group: breast cancer for the University of Chicago Phase II Consortium (P2C) between 2011-2014. Furthermore, Dr. Chumsri also receives several funding supports from the Department of Defense, National Cancer Institute, Foundations, and pharmaceutical companies to conduct novel clinical trials in Immuno Oncology as well as Cancer Vaccine for both treatment and prevention of breast cancer. Currently, Dr. Chumsri is serving as the leader in the Experimental Trials for Precision Medicine at the Jacoby Center for Breast Health at Mayo Clinic Florida. Dr. Chumsri also serve in several important committees at Mayo Clinic Florida, including Cancer Center Scientific Progress Review Subcommittee, Fellowship Program Education Committe

    • Dr. Chumsri - Medical Oncologist & Breast Cancer Treatment - Mayo Clinic

    A diagnosis of cancer is often followed by myriad doctor appointments and many questions.Dr. Saranya Chumsri, a medical oncologist, typically sees women afte...

    Dr. Chumsri - Breast cancer and COVID19

    The COVID-19 pandemic has made it difficult for some patients to keep on track with their regular breast cancer screenings. In the beginning of the pandemic,...

Education & Training

  • University of Maryland
    University of MarylandFellowship, Hematology and Medical Oncology, 2005 - 2008
  • Albert Einstein Healthcare Network
    Albert Einstein Healthcare NetworkResidency, Internal Medicine, 2002 - 2005
  • Chulalongkorn University Faculty of Medicine
    Chulalongkorn University Faculty of MedicineClass of 1999

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2014 - 2026
  • SC State Medical License
    SC State Medical License 2024 - 2025
  • MD State Medical License
    MD State Medical License 2008 - 2024
  • PA State Medical License
    PA State Medical License 2002 - 2005
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Outstanding Research Award Mayo Clinic, 2019
  • The Physician Colleague (Attending) - Special Achievement Award, Nursing Excellence Awards University of Maryland Medical Center, 2013
  • Sonia Stupniker, M.D. Library Award, In Recognition of Outstanding Achievement in Scholarly Activity Albert Einstein Medical Center, 2005
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings:...  
    Bhatnagar B, Gilmore S, Goloubeva O, Pelser C, Medeiros M, Chumsri S, Tkaczuk K, Edelman M, Bao T, Springerplus, 7/1/2014
  •  
    Guha P, Bandyopadhyaya G, Polumuri SK, Chumsri S, Gade P, Kalvakolanu DV, Ahmed H, Breast Cancer Res Treat, 5/1/2014
  • Circulating Giant Macrophages as a Potential Biomarker of Solid Tumors  
    Adams D, Martin S, Alpaugh K, Charpentier M, Tsai S, Bergan R, Ogden IM, Catalona W, Chumsri S, Tang CM, Cristofanilli, Proc Natl Acad Sci USA, 2/18/2014
  • Join now to see all

Books/Book Chapters

  • Estrogen Action, SERMS and Women’s Health 
    Chapter: Advances with Aromatase Inhibitors. 
    Chumsri S, Bao T, Sabnis G, Brodie AEditors: V. Craig Jordan.World Scientific, Singapore2011
  • AACR Educational Book 
    Chapter: Review Article: Leukemic stem cell pathways – therapeutic implications. 
    Chumsri S, Matsui W, Burger AM2008
  • Cancer Research Journal 
    Chapter: Cancer stem cells. 
    Page 1935 - 2506Chumsri S, Burger AMEditors: Frank Columbus.Nova Science Publishers, Inc.2008

Abstracts/Posters

  • HER2 regulated miRNA expression in letrozole resistant breast cancer.
    Kazi A, Sabnis G, Zhou Q, Chumsri S, Schech A, Shah P, Brodie A, AACR Annual Meeting, 1/1/2014
  • Effect of diet-induced obesity on MCF-7Ca xenografts grown in ovariectomized athymic nude mice.
    Sabnis G, Goloubeva O, Shah P, Chumsri S, Brodie A, AACR Annual Meeting, 1/1/2014
  • Cancer in HIV-Positive Women: Clinicopathologic Features and Comparison with General Population.
    Kokh D, Rosenblatt R, Chumsri S, Kesmodel S, Ioffe O, The United States & Canadian Academy of Pathology’s 103rd Annual Meeting, 1/1/2014
  • Join now to see all

Lectures

  • Effects of immune architecture on response to adjuvant capecitabine in triple-negative breast cancer (FinXX trial). 
    2019 ASCO Annual Meeting - 6/1/2019
  • Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoAL... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • Balancing Efficacy with Tolerability in the Management of Metastatic Breast Cancer 
    Florida Hospital Fish Memorial Cancer Institute, Orange City, FL - 5/9/2014
  • Join now to see all

Press Mentions

  • The Future Will Be Personalized: Accelerating Microbiome Research
    The Future Will Be Personalized: Accelerating Microbiome ResearchNovember 24th, 2022
  • Cancer Treatment May Inhibit Immune Response to Covid Vaccine
    Cancer Treatment May Inhibit Immune Response to Covid VaccineJanuary 23rd, 2022
  • Study Finds Cancer Treatment Might Inhibit Immune Therapy to Covid-19 Vaccination
    Study Finds Cancer Treatment Might Inhibit Immune Therapy to Covid-19 VaccinationJanuary 22nd, 2022
  • Join now to see all

Grant Support

  • Efficacy and Safety of COVID-19 Vaccine in Cancer PatientsMayo Clinic2021–Present
  • A Pilot Trial of Preoperative Oral Microbiota-Based Investigational New Drug, RBX7455 to Target Immune Response in Patients with Operable Stage I-III Breast CancerRebiotix2021–Present
  • A multi-antigen vaccine for the primary prevention of breast cancerNCI DCP PREVENT2020–Present
  • Phase I/II Trial of Pembrolizumab in combination with Binimetinib in unresectable locally advanced or metastatic triple negative breast cancerDOD Breakthrough Award2018–Present
  • Phase I/II Trial of Pembrolizumab in combination with Binimetinib in unresectable locally advanced or metastatic triple negative breast cancerMerck and Pfizer2017–Present
  • Spatial analysis of the immune landscape in breast cancerDOD Breakthrough Award2016–Present
  • Spatial analysis of the immune landscape in breast cancerBreast Cancer Research Foundation2020–2021
  • Genomic analysis of ERBB2 activity and expression in HER2 tumor cellsBreast Cancer Research Foundation2019–2020
  • Genomic analysis of ERBB2 activity and expression in HER2Breast Cancer Research Foundation2018–2019
  • Genomic analysis of ERBB2 activity and expression in HER2Breast Cancer Research Foundation2017–2018
  • Engineering gut microbiome to target breast cancerMayo Clinic Cancer Focused Research Team2017–2018
  • Epigenetic Modulation as Novel Treatment for Triple Negative Breast CancerSusan G. Komen for the Cure2013–2017
  • Phase II clinical trial of carfilzomib in triple negative breastMayo Clinic Cancer Focused Research Team2015–2016
  • phase II protocol of binimetinib in combination with letrozole in postmenopausal women with advanced endocrine resistant breast cancerMayo Clinic Scholarly Opportunity Initiative2014
  • Early Therapeutics Development with Phase 2 EmphasisNIH2013–2014
  • A Pilot Phase II Study of Everolimus, Lapatinib, and Letrozole in Postmenopausal Women with Advanced Endocrine Resistant Breast Cancer.Novartis and GSK2012–2014
  • Sulforaphane and Breast CancerAmerican Cancer Society2012–2014
  • MiR-140 and Breast Cancer PreventionNIH2012–2014
  • Targeting the cytoskeletal physics of circulating breast tumor cellsDOD/ CDMRP2011–2014
  • Targeting microtentacles on circulating breast tumor cellsSusan G. Komen for the Cure2010–2013
  • A Pilot and Phase II Study of Vorinostat and Lapatinib in Women with Local Recurrent or Metastatic Breast Cancer to Evaluate Response and Surrogate Biomarkers of EMT and Breast CSCsGSK and Merck2010–2012
  • Aurora Kinase and Taxanes ResistanceAMGEN Fellowship Award Grant2007–2008

Committees

  • Committee member, Mayo Clinic Florida Clinical Trials Leadership Council 2020 - Present
  • Committee member, Mayo Clinic Florida Fellowship Program Education Committee 2020 - Present
  • Committee member, Mayo Clinic Florida Fellowship Interview Committee 2019 - Present
  • Committee member, (Neo)ALTTO steering committee 2019 - Present
  • Committee member, ACCRU Consortium Breast Cancer Committee 2019 - Present
  • Committee member, The Alliance for Clinical Trials in Oncology Immuno-Oncology Committee 2019 - Present
  • Committee member, Cancer Center Scientific Progress Review Subcommittee at Mayo Clinic 2015 - Present

Professional Memberships

Other Languages

  • Thai

Hospital Affiliations

External Links

  • Mayo Clinic Biohttps://www.mayoclinic.org/biographies/chumsri-saranya-m-d/bio-20114242
  • Refer a Patienthttp://www.mayoclinic.org/medical-professionals/provider-relations/refer-a-patient

Dr. Saranya Chumsri, Dr. Saranya Chumsri, MD, Dr. S Chumsri